Direct evidence implicating the asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase 1 (DDAH1) pathway in cerebrovascular dysfunction and stroke pathogenesis in mice.
- DOI
- 10.1111/bph.70556
- Published
- 2026 Jul 31
- Container
- British journal of pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/bph.70556,
title = {Direct evidence implicating the asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase 1 (DDAH1) pathway in cerebrovascular dysfunction and stroke pathogenesis in mice.},
author = {Flynn A and Riddell A and Bernard A and Haggarty J and Weidt S and Alenazi J and Trabold E and Graham D and Dowsett LB and Leiper J and Miller AA},
year = {2026},
journal = {British journal of pharmacology},
doi = {10.1111/bph.70556},
url = {https://doi.org/10.1111/bph.70556}
}RIS
TY - JOUR TI - Direct evidence implicating the asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase 1 (DDAH1) pathway in cerebrovascular dysfunction and stroke pathogenesis in mice. AU - Flynn A AU - Riddell A AU - Bernard A AU - Haggarty J AU - Weidt S AU - Alenazi J AU - Trabold E AU - Graham D AU - Dowsett LB AU - Leiper J AU - Miller AA PY - 2026 JO - British journal of pharmacology DO - 10.1111/bph.70556 UR - https://doi.org/10.1111/bph.70556 ER -
APA
A, F., A, R., A, B., J, H., S, W., J, A., E, T., D, G., LB, D., J, L., & AA, M. (2026). Direct evidence implicating the asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase 1 (DDAH1) pathway in cerebrovascular dysfunction and stroke pathogenesis in mice.. British journal of pharmacology. https://doi.org/10.1111/bph.70556
Source records
- pubmed · retrieved 2026-09-25T00:25:41.847Z